Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 3
2019 6
2020 4
2021 5
2022 6
2023 2
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Citations

3 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.
Conforti F, Pala L, Bagnardi V, De Pas T, Martinetti M, Viale G, Gelber RD, Goldhirsch A. Conforti F, et al. Lancet Oncol. 2018 Jun;19(6):737-746. doi: 10.1016/S1470-2045(18)30261-4. Epub 2018 May 16. Lancet Oncol. 2018. PMID: 29778737
BACKGROUND: Despite the acknowledged sex-related dimorphism in immune system response, little is known about the effect of patients' sex on the efficacy of immune checkpoint inhibitors as cancer treatments. We did a systematic review …
BACKGROUND: Despite the acknowledged sex-related dimorphism in immune system response, little is known about the effect of patient …
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
Duan J, Cui L, Zhao X, Bai H, Cai S, Wang G, Zhao Z, Zhao J, Chen S, Song J, Qi C, Wang Q, Huang M, Zhang Y, Huang D, Bai Y, Sun F, Lee JJ, Wang Z, Wang J. Duan J, et al. JAMA Oncol. 2020 Mar 1;6(3):375-384. doi: 10.1001/jamaoncol.2019.5367. JAMA Oncol. 2020. PMID: 31876895 Free PMC article.
STUDY SELECTION: All randomized clinical trials that compared anti-PD-1 and anti-PD-L1 with standard treatment in patients with cancer were selected as candidates. Retrospective studies, single-arm phase 1/2 studies, and trials comparing anti-PD-1 and anti-PD-L1 wit …
STUDY SELECTION: All randomized clinical trials that compared anti-PD-1 and anti-PD-L1 with standard treatment in patients with ca …
Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis.
Cerrato C, Crocerossa F, Marchioni M, Giannarini G, Gupta S, Albiges L, Brouwer O, Albersen M, Fankhauser C, Grimm MO, Gandaglia G, Roupret M, Mir MC; ESOU Board. Cerrato C, et al. Eur Urol Oncol. 2024 Oct;7(5):1005-1014. doi: 10.1016/j.euo.2024.03.014. Epub 2024 Apr 21. Eur Urol Oncol. 2024. PMID: 38644155 Review.
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) herald a transformative era in metastatic renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) treatment, amid acknowledged sex-based disparities in these cance …
BACKGROUND AND OBJECTIVE: Immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) herald a transformative era in metastatic …
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U, Tsourti Z, Vervita K, Peters S. Dafni U, et al. Lung Cancer. 2019 Aug;134:127-140. doi: 10.1016/j.lungcan.2019.05.029. Epub 2019 May 30. Lung Cancer. 2019. PMID: 31319971
This network meta-analysis (NMA), based on 12 phase-III studies with 9,236 metastatic NSCLC patients, aims to compare the efficacy of treatments including at least one immune-checkpoint inhibitor (ICI) with or without chemotherapy, as frontline therapy …
This network meta-analysis (NMA), based on 12 phase-III studies with 9,236 metastatic NSCLC patients, aims to compare t …
Antibiotic treatment and survival in non-small cell lung cancer patients receiving immunotherapy: a systematic review and meta-analysis.
Abdelhamid A, Tuminello S, Ivic-Pavlicic T, Flores R, Taioli E. Abdelhamid A, et al. Transl Lung Cancer Res. 2023 Dec 26;12(12):2427-2439. doi: 10.21037/tlcr-23-597. Epub 2023 Dec 22. Transl Lung Cancer Res. 2023. PMID: 38205205 Free PMC article.
Despite their efficacy, responses to ICIs have been shown to differ based on several factors; for example, antibiotic use prior to and/or during immunotherapy has been associated with lower survival in NSCLC patients. The objective of this study is to provide …
Despite their efficacy, responses to ICIs have been shown to differ based on several factors; for example, antibiotic use prior to an …
Relationship between Patients' Baseline Characteristics and Survival Benefits in Immunotherapy-Treated Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Hu X, Liu Y, He Y, Wang Z, Zhang H, Yang W, Lu J. Hu X, et al. J Oncol. 2022 May 19;2022:3601942. doi: 10.1155/2022/3601942. eCollection 2022. J Oncol. 2022. PMID: 35646119 Free PMC article. Review.
However, little is known about whether these factors affect the efficacy of immune checkpoint inhibitors (ICIs) in patients with advanced non-small-cell lung cancer (NSCLC). Therefore, we performed this systematic review and meta-analy …
However, little is known about whether these factors affect the efficacy of immune checkpoint inhibitors (ICIs) in patients wi …
Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.
Takada K, Shimokawa M, Mizuki F, Takamori S, Takenaka T, Miura N, Shikada Y, Yoshizumi T. Takada K, et al. Eur J Med Res. 2022 Aug 23;27(1):157. doi: 10.1186/s40001-022-00789-7. Eur J Med Res. 2022. PMID: 35999618 Free PMC article. Review.
INTRODUCTION: Recently, several meta-analyses have investigated the association between sex and the efficacy of immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC). ...METHODS: We searched PubMed and Scopus from database inception to Feb …
INTRODUCTION: Recently, several meta-analyses have investigated the association between sex and the efficacy of immune checkpo …
Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials.
Conforti F, Pala L, Pagan E, Corti C, Bagnardi V, Queirolo P, Catania C, De Pas T, Giaccone G. Conforti F, et al. ESMO Open. 2021 Oct;6(5):100251. doi: 10.1016/j.esmoop.2021.100251. Epub 2021 Aug 26. ESMO Open. 2021. PMID: 34455288 Free PMC article. Review.
BACKGROUND: In our previous works, we demonstrated that patients' sex affects the efficacy of immune checkpoint inhibitors (ICIs) in patients with several advanced solid tumors. ...METHODS: We carried out a systematic review and meta …
BACKGROUND: In our previous works, we demonstrated that patients' sex affects the efficacy of immune checkpoint inhibit …
Impact of Patients' Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis.
Hassler MR, Abufaraj M, Kimura S, Stangl-Kremser J, Gust K, Glybochko PV, Schmidinger M, Karakiewicz PI, Shariat SF. Hassler MR, et al. Clin Genitourin Cancer. 2020 Apr;18(2):88-94.e2. doi: 10.1016/j.clgc.2019.09.004. Epub 2019 Sep 27. Clin Genitourin Cancer. 2020. PMID: 31668768
Recent meta-analyses on checkpoint inhibitors in cancer report conflicting data regarding the association of patient gender with inhibitor efficacy. ...We aimed to assess the efficacy of immunotherapy according to patient gender in advanc …
Recent meta-analyses on checkpoint inhibitors in cancer report conflicting data regarding the association of patient gender wi …
Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis.
Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, Pennacchioli E, Cocorocchio E, Ferrucci PF, De Marinis F, Gelber RD, Goldhirsch A. Conforti F, et al. J Natl Cancer Inst. 2019 Aug 1;111(8):772-781. doi: 10.1093/jnci/djz094. J Natl Cancer Inst. 2019. PMID: 31106827 Free PMC article.
The first included all randomized controlled trials (RCTs) testing anti-PD1 and anti-PD-L1 plus chemotherapy vs chemotherapy to assess different efficacy between men and women. The second included all RCTs of first-line systemic treatment in advanced non-small cell lung …
The first included all randomized controlled trials (RCTs) testing anti-PD1 and anti-PD-L1 plus chemotherapy vs chemotherapy to assess diffe …
29 results